|
|
|||||||
Amyloidosis |
From the Division of Hematology (MAG, MQL, AD, SRH, SKK, DAG) and the Division of Nephrology and Hypertension (NL), Mayo Clinic, Rochester, Minnesota, USA
Correspondence: Morie A. Gertz, MD, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: gertz.morie{at}mayo.edu
Our objective was to determine whether the goal of high-dose therapy should be a partial hematologic response or a complete response. We analyzed 282 consecutive stem cell transplant patients. A partial hematologic response was achieved in 108 patients (38%), and 93 (33%) achieved a complete hematologic response. Survival rates of patients with complete, partial, or no response were significantly different (p<0.001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival.
Key words: amyloidosis, chemotherapy, complete response, immunoglobulin free light chain, stem cell transplant, survival.
Related Article
Haematologica 2007 92: 1302-1307.
This article has been cited by other articles:
![]() |
R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |